Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

DON'T BUY

Still cautious on this stock. Starting to get some generic competition on Wellbutrin. Has a lot of debt. Looks cheap. There is an investigation with FCC that needs to be cleared up.

HOLD

The stock is now looking ahead rather than at the quarter that was just reported. On a long-term basis it looks quite promising.

BUY

Could get a positive surprise out of this company. Any sort of good news, you are going to get a pop on it.

DON'T BUY

Starting to look interesting at these levels but there could be further weakness. There are a lot of issues going on with the company so doesn't expect the stock will move up anytime soon.

DON'T BUY

Not interested in the stock at all. Too many grey zones surrounding the company and management. Wouldn't be surprised if the credit agencies downgrade this company.

BUY

Even with all the earnings announcements and the bad news, their model price is $32.

DON'T BUY

Would want to see a couple of quarters of clean numbers. Also under SEC investigation.

DON'T BUY

Too many investigations going on. Increased competition coming on for their products.

DON'T BUY

Wouldn't touch it with a 10 foot pole. Numbers are suspect. Management is not believable. Risky.

DON'T BUY

Accounting issues are a concern. Has a hard time understanding how you can build a 10, 15, 20-year model on a company with so much potential competition.

DON'T BUY

Not a fan of this company.

DON'T BUY

Stay away from turn around situations. Stay away.

WATCH

Wouldn't touch at the moment. Credibility problem, can they trust accounting. Speculative. Has some good businesses.

DON'T BUY

Can only take bad accounting for so long before you leave.

DON'T BUY

A good company with some good assets in its. Mired in a lot of issues with the OCC and FCC and feels that top management is not focused on their business.

Showing 436 to 450 of 714 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)